Ferozsons Laboratories Limited (hereafter as “Ferozsons” or “the Company”) was incorporated as a private limited company on 28 January 1954 and commenced its commercial operations in 1956. The Company was converted into a public limited company on 08 September 1960 and subsequently got listed on the Pakistan Stock Exchange (PSX) in 1960. The registered office is at 197-A, The Mall, Rawalpindi, and the manufacturing facility is in Nowshera, Khyber Pakhtunkhwa. The consolidated group comprises three entities: Ferozsons Laboratories Limited (the Holding Company), BF Biosciences Limited (subsidiary, 57.36% holding), and Farmacia (a retail pharmacy partnership with 98% held interest).

The Ferozsons business group traces its origins to 1894, when Maulvi Ferozuddin Khan founded the Ferozsons publishing house. From its inception, the group was guided by a corporate vision to make a meaningful contribution to education and healthcare, particularly for underprivileged communities across the subcontinent. In 1960, Ferozsons Laboratories Limited became the first Pakistani pharmaceutical company to be listed on the Pakistan Stock Exchange (formerly Karachi Stock Exchange). Later in 2006, the Company entered into a joint venture with Argentina’s Bagó Group to establish Pakistan’s first Biotech plant through its subsidiary, BF Biosciences Limited. The Group’s global network then grew to include trusted international partners such as BioGaia of Sweden, to introduce premium Swedish probiotics in Pakistan, Butterfly’s for their US FDA portable ultrasound machines, and Nihon Kohden of the Middle East, for their medical devices. Then, in 2008, the Company partnered with Boston Scientific, USA, for the distribution of medical devices in Pakistan. In 2014, the Company introduced the first oral Hep C treatment in Pakistan and the start of a Voluntary Licensing Partnership with Gilead Sciences. In 2020, in COVID times, the Company introduced a vaccine, named Remdesivir, to treat hospitalized patients with severe COVID-19 disease. In 2024, Ferozsons became 1 of the 6 global licensees to have successfully signed a voluntary license agreement with Gilead Sciences for the manufacture and sale of licensed generic Lenacapavir.

Ferozsons Laboratories Limited is primarily engaged in the import, manufacturing, and sale of pharmaceutical products and medical devices. The Company manages a diverse portfolio, strengthened by strategic international partnerships. Its product range includes branded generics and in-licensed treatments, with a primary focus on cardiology, gastroenterology, hepatology, dermatology, and anti-infective therapies. The Company is also expanding into other therapeutic areas with growing clinical demand, such as diabetes, metabolic health, pediatrics, and women’s health. Ferozsons operates a fully compliant current Good Manufacturing Practices (cGMP) production facility in Nowshera, which is ISO 9001 certified and equipped with advanced manufacturing and quality testing equipment. Its production capabilities encompass a wide range of dosage forms, including tablets, capsules, syrups, suspensions, creams, and ointments. The following table presents the Company’s actual production levels and corresponding capacity utilization rates.

Ownership is concentrated within the Waheed family. The sponsoring family owns ~48% of the shareholding of the Company. NIT & ICP (~4%), Banks & Non-banking financial institutions (~6%), Insurance Companies (~4%), Mudarabas & Mutual Funds (~10%). The remaining shares (~29%) are held by the General Public and other Companies.

The Company's ownership structure is considered stable, having remained under the control of the current sponsors for several decades, with no changes expected in the foreseeable future. However, succession planning at the key-owner level is not formally documented in publicly available materials. Given the family-controlled nature of the enterprise and the dual CEO/Chairperson roles within one family, this represents a key-person risk element that PACRA monitors.

The sponsoring family has been actively involved in the pharmaceutical sector for over six decades, consistently demonstrating strong business acumen. Their core strengths include forging international partnerships and developing strategic alliances with leading organizations in the global healthcare industry. This enduring commitment to excellence has allowed the group to effectively navigate the complexities of the pharmaceutical landscape, fostering sustained growth and continuous innovation.

Ferozsons Laboratories Limited is one of Pakistan’s long-established pharmaceutical companies, recognized for its commitment to excellence, innovation, and responsible growth. A multiple-time recipient of the Pakistan Stock Exchange (PSX) Top 25 Companies Award, the Company has consistently demonstrated adequate financial performance. In 2006, Ferozsons partnered with Argentina’s Bagó Group to establish BF Biosciences Limited, a biopharmaceutical company and pioneer in the next-stage biotech plant in Pakistan, holding an initial ~80% stake. Following BF Biosciences’ listing on the PSX in October 2024, Ferozsons now holds a 57.36% share, while the Bagó Group retains 14.34%. Ferozsons also serves as the marketing and distribution partner in Pakistan for several global healthcare leaders, including Gilead Sciences Inc. (viral hepatitis and HIV), Boston Scientific Corporation (interventional medical devices), Nihon Kohden (diagnostic and monitoring technologies), and BioGaia (probiotic health solutions). The group’s enduring financial strength is supported by its ability to forge strategic alliances and long-term international partnerships, reinforcing its leadership in Pakistan’s healthcare sector.

The board comprises seven members: four non-executive directors (including the chairperson), two independent directors, and one executive director who also serves as the CEO. This diverse composition ensures compliance with the corporate governance code.

All members of the Board of Directors (BoD) are seasoned professionals with extensive industry experience and long-standing affiliations with the company. Each member brings a unique skill set, ensuring a well-balanced and experienced leadership team. 

The Chairperson, Mrs. Akhtar Khalid Waheed, has been an integral part of the Board since 1992 and has played a pivotal role in the Company’s continued success.

The Board also includes independent directors Mr. Suleman Ghani and Mr. Arshad Saeed, both of whom bring over three decades of experience across various sectors, including the multinational healthcare and pharmaceutical companies.

Among the non-executive directors is Mr. Shahid Anwar, who has previously served on the boards of prominent organizations such as Bata Pakistan, Lafarge Cement, and Soneri Bank. He currently heads the MD’s Secretariat and Personnel Department at NIT.

Mrs. Amna Piracha Khan and Mrs. Munize Azhar Paracha further strengthen the Board with their diverse professional backgrounds and extensive expertise.

This depth of experience and diversity of perspectives significantly strengthen Ferozsons’ governance framework and support the Company’s long-term strategic objectives.

The board of Ferozsons Laboratories Limited has established three key committees to enhance its effectiveness: the Audit Committee, the Investment Committee, and the HR & Remuneration Committee. Each of these committees is chaired by an independent director, ensuring impartial oversight and robust governance. Throughout the year 2024-25, five board meetings were held, with adequate attendance from all board members. The minutes of these meetings are meticulously documented, reflecting the board’s commitment to transparency and accountability. However, it is noteworthy that the majority of the board members are from the sponsoring family.

Ferozsons Laboratories Limited demonstrates a strong commitment to financial transparency. The Company’s external auditors are M/S KPMG Taseer Hadi & Co. Chartered Accountants, a firm recognized as one of the Big-4 with a satisfactory QCR rating and classified in category ‘A’ by the SBP. For the financial year ended June 2025, the firm expressed an unqualified opinion on the Company’s financial statements. 

The Company boasts a well-defined organizational structure, comprising eight functional and administrative departments. Each department operates with a multilayered hierarchy and is led by a qualified department head. These department heads report directly to the CEO and COO, ensuring streamlined communication and effective management. Currently, all key positions within the organization are fully staffed, reflecting the Company’s commitment to maintaining a robust and efficient workforce.

The management team at Ferozsons Laboratories Limited is composed of qualified professionals with extensive skills and long-standing associations with the company. The CEO, Mr. Osman Khalid Waheed, is a Harvard graduate and possesses over 30 years of experience. Additionally, he holds several directorships in other blue-chip companies such as Packages Limited, Pakistan Center for Philanthropy, and National Management Foundation. His leadership and vision have been instrumental in steering the Company towards sustained growth and innovation. Mr. Omar Khalid Waheed, the Vice President, is a chemical engineer whose expertise is particularly relevant to the pharmaceutical sector. This leadership is assisted by a team of seasoned professionals, including the newly appointed CFO, Mr. Shahid Tofique. He is a qualified chartered accountant with more than two decades of professional experience with a specialized, long-standing focus on Pakistan’s pharmaceutical sector. This background equips him with a deep, practical understanding of the sector’s distinct matters. Together, they are supported by a strong team of seasoned professionals, ensuring operational excellence, financial discipline, and strategic alignment.

The Company has established clear reporting lines, further enhanced by the presence of a management committee that includes all chiefs and directors of various departments. This committee meets weekly to discuss key operational and strategic matters, ensuring cohesive and effective management. However, the minutes of these meetings are not formally documented as per the management’s representation. Management depth below the executive level has been strengthened through the CFO and an internal audit function, providing reasonable operational resilience.

Ferozsons has implemented SAP S/4 HANA by SAP SE, Walldorf, Germany, ensuring compliance with global standards for enterprise management systems. This advanced platform provides a real-time, end-to-end integrated solution for operations across various functions, including finance, sales and marketing, production, procurement, quality management, and human capital management. The adoption of SAP S/4 HANA enhances operational efficiency, data accuracy, and decision-making capabilities.

Ferozsons Laboratories Limited maintains a robust control environment through a detailed Management Information System (MIS). This system, which features key performance indicators, is submitted to the Chairman/CEO/CFO on a regular basis. To ensure compliance with the Company’s policies and operating procedures, Ferozsons has outsourced its internal audit function to EY Ford Rhodes, Chartered Accountants, a Big-4 firm. This partnership enhances the Company’s internal controls and ensures adherence to the highest standards of corporate governance.

Pakistan’s pharmaceutical industry has exhibited sustained structural expansion, with the total market reaching PKR 1,182.6 billion on a MAT basis as of January 2026, reflecting robust growth of 15.2% and a 5-year MAT CAGR of 17.2%. This consistent double-digit trajectory underscores the sector’s resilience relative to the broader economy and is fundamentally anchored in strong, non-cyclical demand drivers. Pakistan’s population of over 230 million, growing at ~2% annually, provides a steadily expanding consumption base; however, the more critical driver is the country’s elevated disease burden. The exceptionally high prevalence of non-communicable diseases (NCDs), with diabetes affecting 30.8% of the adult population, alongside widespread cardiovascular and renal conditions, and the world’s largest hepatitis B and C patient pool, creates structurally recurring demand for pharmaceutical products, rendering the sector relatively insensitive to economic cycles. Complementing these demand fundamentals, regulatory developments, most notably DRAP’s phased deregulation of non-essential medicine prices since CY22, have enabled partial pass-through of accumulated cost inflation, supporting revenue growth in value terms. As a result, overall market expansion reflects a combination of steady volume growth (~5–7%) and price-driven gains (~8–10%). Additional tailwinds, including rising generic penetration, favorable import substitution economics, expanding healthcare infrastructure in Tier-2 cities, and improving health awareness, further reinforce this growth momentum. Given the low per capita pharmaceutical spend of USD 20–25 relative to USD 60+ in comparable markets, the industry remains underpenetrated, supporting a sustained above-GDP growth outlook.

Within this broader expansion, Pakistan’s therapeutic landscape reflects a dual burden of infectious diseases and a rapidly expanding NCD load. The Alimentary & Metabolism segment is the largest category at an estimated 18–20% of market value, driven by the anti-diabetic sub-segment, oral hypoglycemics, insulins, and the emerging GLP-1 class, with Pakistan’s acute diabetes and obesity burden ensuring above-market growth rates. Anti-Infectives represent the second-largest segment at 15–17%, supported by high infectious disease prevalence, though the segment faces a structural headwind from antimicrobial resistance (AMR): Pakistan ranks 176th out of 204 nations in AMR-related mortality, with regulatory pressure on irrational antibiotic use gradually moderating volume growth prospects. The Cardiovascular segment (12–14%) is among the fastest-growing clusters, driven by the convergence of hypertension, dyslipidemia, diabetes, and chronic kidney disease, generating compound demand for combination therapies. CNS (8–10%) and Respiratory (7–9%) segments are growing steadily, while the Hepatology and Antiviral segment, though smaller at 4–5%, carries strategic significance given Pakistan’s hepatitis burden and government-sponsored elimination programs. Notably, the highest-demand therapeutic categories, anti-diabetics, cardiovascular agents, and anti-infectives, fall predominantly within DRAP’s essential medicines framework, subjecting them to price controls.

The competitive landscape reflects a moderately concentrated top tier alongside a fragmented base of smaller players, where the leading ten companies command 44.6% of total market revenues. A notable structural shift is the increasing dominance of well-capitalized local champions over multinational corporations (MNCs), a transition driven by the local players’ superior price competitiveness and localized manufacturing cost advantages. Moving forward, DRAP’s increasingly stringent enforcement of Good Manufacturing Practices (GMP) is expected to accelerate industry consolidation, disadvantaging non-compliant smaller players and redirecting market share toward well-capitalized, top-tier manufacturers.

Looking ahead, the sector’s outlook remains favorable, anchored in strong demand fundamentals, continued regulatory support in selected areas, and easing monetary conditions, which may enhance investment capacity and operational efficiency. At the same time, risks emanating from macroeconomic instability, energy cost pressures, geopolitical developments affecting API supply, characterized by an 85–90% reliance on imported Active Pharmaceutical Ingredients (APIs), predominantly sourced from China, and affordability concerns remain pertinent. Overall, the industry is expected to maintain its growth trajectory, with long-term potential supported by low per capita consumption, expanding export opportunities, and gradual evolution toward higher-value segments such as specialty therapeutics and biologics, although the sustainability of margins will depend on the sector’s ability to navigate external shocks and regulatory constraints effectively.

Ferozsons Laboratories Limited maintains a diversified and well-entrenched presence across key therapeutic segments, with a portfolio exceeding 100 brands spanning cardiology, diabetes, hepatology, gastroenterology, dermatology, and related areas. The Company has established a meaningful domestic footprint while progressively expanding its international reach to over 30 low- and middle-income countries (LMICs), catering to diverse and underserved healthcare needs. As per the latest IQVIA report (MAT Jan-26), Ferozsons is positioned at 21st place in the pharmaceutical industry, with consolidated revenues of ~PKR 19bln. The Company’s standalone portfolio is characterized by broad-based competitive strength across multiple therapeutic categories, featuring several market-leading brands: 

Overall, the Company has established an adequate presence across multiple therapeutic niches, supported by a reasonably diversified molecule portfolio. Further, the growth potential embedded in its existing molecule base, across both volume expansion and product lifecycle deepening, provides a credible foundation for incremental market share gains over the medium term, subject to sustained commercial execution and portfolio development.

During 1HFY26, Ferozsons Laboratories Limited reported consolidated sales of PKR 12,622mln, on the back of in-market generic sales’ volume-led growth. This performance reflects an annualized growth of ~33.9% against the prior year, continuing a strong upward historical trajectory (PKR 18,857mln in FY25; PKR 15,855mln in FY24; and PKR 11,457mln in FY23). On a standalone basis, the Company’s net sales closed at PKR 8,289mln, depicting a YoY growth of 19.6%. The revenue composition underwent a structural shift over the years; pharmaceutical products expanded to represent ~80% of total sales as of 1HFY26 (up from ~74% in FY25 and ~68% in FY24), and the remaining is contributed by the medical devices segment to ~20%. Within the pharmaceutical portfolio, the sales mix leans toward non-essential medicines (~65%) over essential medicines (~35%). Topline generation remains anchored by flagship brands OMEGA and Carveda, which contributed ~PKR 574mln (~6.9%) and ~PKR 545mln (~6.6%), respectively, during the half-year. Geographically, the revenue base remains stable and highly concentrated in the domestic market at ~93.3%, with exports providing a steady ~6.7% contribution.

The Company demonstrated sustained expansion in its gross profit margin, which reached ~44.8% in 1HFY26 (FY25: ~42.4%, FY24: ~40.8%, FY23: ~37.2%). This improvement was primarily driven by a favorable shift in the sales mix. Despite these gains at the gross level, the operating margin remained relatively stable at ~11.5% in 1HFY26 (FY25: ~11.4%, FY24: ~11.5%, FY23: ~8.7%). This stagnation indicates that the gross margin improvements were offset by higher operating expenses, specifically stemming from a recent field force expansion and enhanced sales activities. Moving downward, net profit margins experienced a positive uptick to ~5.3% (FY25: ~4.9%, FY24: ~4.8%, FY23: ~2.6%), largely supported by lower finance costs following a slight reduction in overall borrowings and a reduction in policy rates.

From a sustainability perspective, Ferozsons’ long-term business risk profile is structurally supported by a dual focus on operational efficiency and strategic revenue diversification. Operational sustainability is anchored by recent energy optimization initiatives, specifically the deployment of two 1MW solar power plants, which are expected to yield meaningful cost efficiencies and mitigate energy price volatility. On the commercial front, the Company’s long-term viability is significantly enhanced by high-profile international collaborations. Notably, the October 2024 non-exclusive voluntary licensing agreement with Gilead Sciences, positioning Ferozsons as one of six global partners to manufacture and distribute a generic variant of the HIV treatment lenacapavir across 120 emerging markets, will serve as a strong catalyst for future export growth upon its completion. Execution of this initiative leverages both the Nowshera plant for oral dosages and BF Biosciences (under a CMO arrangement) for injectables. Furthermore, the Company’s proactive pursuit of PIC/S (Pharmaceutical Inspection Co-operation Scheme) certification, targeted for completion within a two-year horizon, is anticipated to solidify its quality moat, facilitating deeper penetration into regulated export jurisdictions and bolstering competitiveness in international tenders. Collectively, these initiatives provide a robust foundation for the Company’s long-term sustainability and market leadership.

Ferozsons demonstrated improved liquidity management in 1HFY26, with the gross working capital cycle contracting to ~142 days (FY25: ~156 days, FY24: ~154 days, FY23: ~166 days). This efficiency was primarily driven by accelerated collections, which reduced average receivable days to ~38 days (FY25: ~46 days, FY24: ~41 days, FY23: ~36 days). Consequently, the Company’s net working capital cycle shortened significantly, settling at ~105 days for the period (FY25: ~126 days, FY24: ~110 days, FY23: ~97 days). Notably, the government institutional receivables of ~PKR 2bln with a substantial portion outstanding beyond 12 months and recoveries being static, predominantly from the medical devices segment, represent a structural liquidity and credit risk. Although an ECL provision of PKR 326mln implies ~10.9% coverage as per the standard, continued delays in collections could necessitate incremental short-term borrowing needs.

The Company maintained a strong coverage profile in 1HFY26, with overall metrics strengthening significantly due to a decrease in total borrowings and lower finance costs amid a favorable interest rate environment. This is evidenced by a substantial expansion in the EBITDA-to-finance-cost ratio, which surged to 9.7x (up from 5.7x in FY25, 3.9x in FY24, and 3.5x in FY23). Similarly, the interest coverage ratio saw a notable improvement, climbing to 7.5x (FY25: 4.3x, FY24: 3.5x, FY23: 1.9x), while the core-coverage ratio also increased to 3.7x (FY25: 2.5x, FY24: 2.3x, FY23: 0.7x). Alongside these expanding coverages, the Company’s debt payback profile remains strong, standing at 0.8x as of Dec’25 (compared to ~1.2x in FY25).

Ferozsons Laboratories Limited continued to maintain a low leveraged structure in 1HFY26, with its overall leverage ratio steadily declining to ~21.7% (down from ~23.1% in FY25, ~29.6% in FY24, and ~30.7% in FY23). Looking at the debt composition as of Dec’25, short-term facilities constituted ~52.8% of total borrowings. This leverage profile indicates a balanced approach to financing, with a significant portion of borrowings being short-term, to meet the working capital requirements.